GO:1903026 negative regulation of RNA polymerase II regulatory region sequence-specific DNA binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1903026 describes any process that stops, prevents, or reduces the frequency, rate, or extent of sequence-specific DNA binding by RNA polymerase II regulatory region binding proteins.
• This regulatory process controls transcription by limiting the occupancy of promoters and enhancers by sequence-specific transcription factors and the general transcription machinery.
• Key molecular mechanisms include SUMO-1 modification of TFIID subunits, which inhibits promoter binding, and kinetic competition between elongation and pausing factor NELF.
• Dynamic recruitment of Ets1 to enhancers during T-cell differentiation exemplifies how negative regulation shapes cell-fate transcriptional programs.
• Dysregulation of this process is implicated in cancer, developmental disorders, and immune pathologies through altered transcription factor availability.
• CRISPR-based knockout, point mutation, knock-in, and overexpression models enable precise dissection of genes mediating this negative regulation.
Description
The Gene Ontology term GO:1903026, negative regulation of RNA polymerase II regulatory region sequence-specific DNA binding, defines a biological process that reduces the ability of proteins to bind specific DNA sequences within regulatory regions recognized by RNA polymerase II. This process is fundamental to transcriptional control because it determines the availability of promoters and enhancers for transcription factor occupancy, thereby influencing gene expression programs. Sequence-specific DNA binding by RNA polymerase II regulatory region binding proteins is a prerequisite for transcription initiation, and its negative regulation provides a layer of control that prevents inappropriate or excessive transcription. Understanding this process is critical for researchers studying gene regulation, as it impacts development, differentiation, and disease states where transcriptional programs are rewired. The term encompasses diverse molecular events, including post-translational modifications of transcription factors, competitive binding by non-productive complexes, and kinetic partitioning of paused polymerases. This article synthesizes authoritative QuickGO data and verified PubMed literature to provide a research-grade overview of GO:1903026, its mechanisms, key genes, and experimental approaches for investigation.
negative regulation of RNA polymerase II regulatory region sequence-specific DNA binding At A Glance
| GO ID | GO:1903026 |
|---|---|
| GO term | negative regulation of RNA polymerase II regulatory region sequence-specific DNA binding |
| Ontology | biological_process |
| Synonym | down regulation of RNA polymerase II regulatory region sequence-specific DNA binding; down-regulation of RNA polymerase II regulatory region sequence-specific DNA binding; downregulation of RNA polymerase II regulatory region sequence-specific DNA binding; inhibition of RNA polymerase II regulatory region sequence-specific DNA binding |
| Major function | Reduces the frequency, rate, or extent of sequence-specific DNA binding by proteins that recognize RNA polymerase II regulatory regions, thereby modulating transcription initiation and elongation. |
| Related processes | Transcription regulation, promoter-proximal pausing, enhancer activation, and signal-dependent gene expression. |
| Key mechanisms | SUMOylation of TFIID subunits, competitive binding by NELF, and dynamic transcription factor recruitment. |
| Disease relevance | Cancer, immune disorders, and developmental abnormalities linked to aberrant transcription factor binding. |
What Is GO:1903026?
GO:1903026 is defined as any process that stops, prevents, or reduces the frequency, rate, or extent of RNA polymerase II regulatory region sequence-specific DNA binding. In other words, it covers biological events that negatively regulate the binding of proteins to specific DNA sequences within regulatory regions that are recognized by RNA polymerase II. This includes mechanisms such as post-translational modification of DNA-binding proteins that abrogate their DNA-binding activity, sequestration of transcription factors away from their target sites, and competitive inhibition by non-DNA-binding partners. The term is a biological process and is distinct from positive regulation (GO:1903025) and from the binding activity itself.
Why Is negative regulation of RNA polymerase II regulatory region sequence-specific DNA binding Important in Cell Biology?
GO:1903026 is important because it governs the accessibility of RNA polymerase II regulatory regions to sequence-specific DNA-binding proteins, a step that is rate-limiting for transcription initiation. By negatively regulating this binding, cells can rapidly shut down or fine-tune transcriptional programs in response to developmental cues, stress, or immune signals. Dysregulation of this process can lead to inappropriate gene activation or silencing, contributing to diseases such as cancer and autoimmunity. Moreover, understanding this term provides a framework for interpreting how post-translational modifications and protein-protein interactions control transcription factor occupancy, which is essential for designing targeted therapeutic strategies.
• Controls the timing and magnitude of gene expression by limiting transcription factor binding to promoters and enhancers.
• Enables rapid transcriptional responses to environmental and developmental signals through reversible inhibition of DNA binding.
• Plays a role in T-cell differentiation by dynamically regulating Ets1 recruitment to enhancers.
• Implicated in cancer when negative regulation is lost, leading to oncogene activation.
• Contributes to immune disorders through aberrant transcription factor availability.
• Provides a mechanism for kinetic control of promoter-proximal pausing via NELF competition.
• Offers targets for therapeutic intervention in diseases driven by transcription factor dysregulation.
• Essential for understanding how post-translational modifications such as SUMOylation impact transcription.
• Facilitates the interpretation of genome-wide binding data by accounting for negative regulatory events.
• Guides the design of CRISPR screens to identify modulators of transcription factor binding.
What Happens During negative regulation of RNA polymerase II regulatory region sequence-specific DNA binding?
Post-translational modification of transcription factors
In simple terms: Adding chemical tags to transcription factors can stop them from binding DNA.
One major mechanism of negative regulation is the covalent attachment of small ubiquitin-like modifier (SUMO) proteins to transcription factors, which can inhibit their DNA-binding activity. For example, SUMO-1 modification of hsTAF5, a subunit of the TFIID complex, inhibits TFIID promoter-binding activity, thereby reducing sequence-specific DNA binding at RNA polymerase II regulatory regions. This modification provides a reversible switch to control transcription initiation.
Competitive inhibition by pausing factors
In simple terms: Other proteins can compete with transcription factors for binding sites, blocking their access.
Negative regulation can occur through kinetic competition between elongation rate and the binding of negative elongation factor (NELF) to the transcription machinery. NELF competes with sequence-specific DNA-binding proteins for interaction with the paused RNA polymerase II complex, thereby reducing the frequency of productive binding at regulatory regions. This mechanism is critical for controlling promoter-proximal pausing and subsequent elongation.
Dynamic transcription factor recruitment and exchange
In simple terms: Transcription factors can be dynamically recruited and removed from enhancers to switch gene programs.
During early T-cell differentiation, the transcription factor Ets1 is dynamically recruited to both nucleosome-occupied and nucleosome-depleted enhancer regions, mediating a transcriptional program switch. Negative regulation of DNA binding can involve the exchange of activating and repressive factors at these enhancers, thereby reducing the binding of specific sequence-specific proteins to RNA polymerase II regulatory regions.
Sequestration and allosteric inhibition
In simple terms: Proteins can be held away from DNA or changed shape so they cannot bind.
Negative regulation may also involve sequestration of transcription factors in the cytoplasm or nucleus, or allosteric changes that prevent DNA binding. Although specific examples are limited in the verified citations, the general principle is that reducing the available concentration of active, DNA-binding-competent factors at RNA polymerase II regulatory regions constitutes a key regulatory node.
Key Genes Involved in GO:1903026 negative regulation of RNA polymerase II regulatory region sequence-specific DNA binding
The following genes and proteins are experimentally implicated in negative regulation of RNA polymerase II regulatory region sequence-specific DNA binding, based on the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| TAF5 | Subunit of TFIID; SUMO-1 modification inhibits TFIID promoter-binding activity | Model to study post-translational control of general transcription factor binding |
| NELF | Competes with elongation for paused polymerase, controlling promoter-proximal pausing | Target for understanding kinetic regulation of transcription |
| Ets1 | Dynamic recruitment to enhancers mediates transcriptional program switch in T-cell differentiation | Model for enhancer-driven lineage specification |
| RNA polymerase II | Core enzyme whose regulatory region binding is negatively regulated | Central to transcription initiation and pausing studies |
| TFIID | General transcription factor complex whose promoter binding is inhibited by SUMOylation | Target for studying general transcription machinery regulation |
| SUMO-1 | Modifier that inhibits TFIID promoter-binding activity | Tool for probing reversible inhibition of DNA binding |
| SV40 early promoter | Model regulatory region for sequence-specific single-strand-binding protein studies | Prototype for understanding promoter recognition |
| Single-strand-binding protein | Stimulates transcription in vitro from SV40 early promoter | Model for sequence-specific DNA binding and its regulation |
| hsTAF5 | Human TAF5; SUMOylation inhibits TFIID promoter binding | Relevant to human transcription regulation studies |
| NELF-A | Subunit of NELF complex involved in pausing | Target for pausing regulation experiments |
| NELF-B | Subunit of NELF complex involved in pausing | Target for pausing regulation experiments |
| NELF-C/D | Subunits of NELF complex involved in pausing | Target for pausing regulation experiments |
| CDK9 | Kinase that phosphorylates NELF and regulates pause release | Indirect modulator of negative regulation |
| BRD4 | Recruits P-TEFb to release paused polymerase | Indirect modulator of negative regulation |
| Ets1 cofactors | Modulate Ets1 recruitment to enhancers | Potential targets for altering enhancer binding |
| Chromatin remodelers | Alter nucleosome occupancy at enhancers, affecting factor binding | Indirect regulators of DNA binding |
| Histone modifiers | Modify chromatin to influence transcription factor access | Indirect regulators of DNA binding |
How Is negative regulation of RNA polymerase II regulatory region sequence-specific DNA binding Regulated?
The process of negative regulation of RNA polymerase II regulatory region sequence-specific DNA binding is itself controlled by signaling pathways that impinge on the modification, localization, and interaction partners of DNA-binding proteins. For instance, SUMOylation of TFIID subunits is a regulated event that can be reversed by desumoylases, providing dynamic control. Similarly, the balance between NELF and elongation factors is modulated by kinases such as CDK9, which phosphorylates NELF and other targets to relieve negative regulation. During T-cell differentiation, extracellular signals drive the dynamic recruitment of Ets1 to enhancers, indicating that developmental cues regulate this process. Thus, upstream signaling and post-translational modification networks tightly control the negative regulation of sequence-specific DNA binding at RNA polymerase II regulatory regions.
negative regulation of RNA polymerase II regulatory region sequence-specific DNA binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TAF5 | Cancer, transcription dysregulation | Knockout or point mutation of SUMOylation sites in cell lines |
| NELF | Immune disorders, developmental defects | Knockdown or knockout of NELF subunits in T cells |
| Ets1 | Leukemia, autoimmune diseases | Knock-in of Ets1 mutants in primary T cells |
| SUMO-1 | Cancer, neurodegeneration | Overexpression or knockout of SUMO-1 in cancer cell lines |
| RNA polymerase II | Broad transcriptional pathologies | Point mutations in RNA polymerase II regulatory regions |
Cancer
Loss of negative regulation of sequence-specific DNA binding can lead to constitutive activation of oncogenic transcription programs. For example, impaired SUMOylation of TFIID subunits might result in enhanced promoter binding and aberrant gene expression, contributing to tumorigenesis. Additionally, dysregulated enhancer binding by factors such as Ets1 has been linked to leukemias and lymphomas.
Immune and developmental disorders
Dynamic regulation of Ets1 binding is essential for proper T-cell differentiation; disruptions in this process can cause immunodeficiencies or autoimmune conditions. Similarly, defects in the kinetic control of promoter-proximal pausing mediated by NELF can alter immune cell gene expression programs.
Viral infections
The SV40 early promoter serves as a model for understanding how sequence-specific single-strand-binding proteins stimulate transcription; viruses may exploit or counteract negative regulation to control their own gene expression. This highlights the broader relevance of this process in host-pathogen interactions.
From negative regulation of RNA polymerase II regulatory region sequence-specific DNA binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does SUMOylation of TAF5 inhibit TFIID promoter binding? | Point mutation of SUMO acceptor lysines in TAF5 (knock-in) |
| What is the role of NELF in promoter-proximal pausing? | Knockout of NELF subunits in cell lines followed by RNA-seq |
| How does Ets1 dynamic binding affect T-cell differentiation? | Knock-in of tagged Ets1 for ChIP-seq in primary T cells |
| Can overexpression of a negative regulator reduce oncogene expression? | Overexpression of SUMO-1 or NELF in cancer cell lines |
| Which genes mediate negative regulation of DNA binding? | CRISPR library screening with a reporter of sequence-specific binding |
| Does a disease-associated mutation alter DNA binding? | Knock-in of patient-derived mutations in transcription factor genes |
How to Study the negative regulation of RNA polymerase II regulatory region sequence-specific DNA binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| ChIP-seq | Genome-wide DNA binding of proteins | Mapping transcription factor occupancy at regulatory regions |
| EMSA | In vitro DNA-binding activity | Assessing effects of modifications on binding |
| Reporter assay | Transcriptional output from a regulatory region | Functional validation of negative regulation |
| Co-IP / mass spectrometry | Protein-protein interactions and modifications | Identifying SUMOylated subunits |
| RNA-seq | Global gene expression changes | Downstream effects of altered DNA binding |
| ATAC-seq | Chromatin accessibility | Indirect measure of factor binding potential |
| CRISPR screen | Phenotypic impact of gene knockouts | Discovering regulators of DNA binding |
| Western blot | Protein expression and modification levels | Validating SUMOylation or knockdown efficiency |
Chromatin immunoprecipitation followed by sequencing (ChIP-seq)
ChIP-seq is used to map the genome-wide binding of sequence-specific transcription factors and RNA polymerase II to regulatory regions. By comparing conditions where negative regulation is active versus inactive, researchers can quantify changes in binding frequency and identify affected promoters and enhancers.
Electrophoretic mobility shift assay (EMSA)
EMSA measures the ability of proteins to bind specific DNA sequences in vitro. It can be used to assess the impact of post-translational modifications, such as SUMOylation, on the DNA-binding activity of factors like TFIID.
Reporter assays
Reporter assays using regulatory regions (e.g., SV40 early promoter) linked to a luciferase or fluorescent gene can quantify the functional consequences of negative regulation on transcription.
Proteomics and co-immunoprecipitation
Mass spectrometry-based proteomics and co-immunoprecipitation can identify interaction partners and post-translational modifications that mediate negative regulation, such as SUMO-1 conjugation to TAF5.
How CRISPR Can Be Used to Study GO:1903026 negative regulation of RNA polymerase II regulatory region sequence-specific DNA binding
Knockout
CRISPR knockout of genes encoding negative regulators, such as NELF subunits or SUMO-1, can be used to assess their requirement for reducing sequence-specific DNA binding at RNA polymerase II regulatory regions. Knockout cell lines followed by ChIP-seq or RNA-seq reveal changes in transcription factor occupancy and gene expression.
Point Mutation
Point mutations can be introduced into specific residues, such as the SUMO acceptor lysine in TAF5, to prevent modification and test its role in inhibiting TFIID promoter binding. This approach provides precise mechanistic insights without altering protein levels.
Knock-in
Knock-in of tagged versions of transcription factors, such as Ets1, allows for dynamic tracking of their recruitment to enhancers using ChIP-seq or live-cell imaging. This helps elucidate how negative regulation shapes transcriptional program switches during differentiation.
Overexpression
Overexpression of negative regulators, such as SUMO-1 or NELF, can be achieved by CRISPR activation or lentiviral delivery. This tests whether increased levels of these factors enhance negative regulation and suppress target gene expression, potentially reversing disease phenotypes.
How EDITGENE Supports negative regulation of RNA polymerase II regulatory region sequence-specific DNA binding Research
Researchers studying negative regulation of RNA polymerase II regulatory region sequence-specific DNA binding-related genes often need to determine whether a candidate gene is causally involved in modulating transcription factor binding. EDITGENE provides a comprehensive suite of CRISPR-based services to enable such investigations, from gene knockout to precise point mutations and library screening.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of RNA polymerase II regulatory region sequence-specific DNA binding research.
Frequently Asked Questions About negative regulation of RNA polymerase II regulatory region sequence-specific DNA binding
What is GO:1903026?
GO:1903026 is a Gene Ontology biological process term that describes any process that stops, prevents, or reduces the frequency, rate, or extent of RNA polymerase II regulatory region sequence-specific DNA binding.
What genes are involved in negative regulation of RNA polymerase II regulatory region sequence-specific DNA binding?
Key genes include TAF5, NELF subunits, Ets1, and SUMO-1, as shown in studies of TFIID inhibition, promoter-proximal pausing, and T-cell differentiation.
How does SUMOylation regulate DNA binding?
SUMO-1 modification of TFIID subunits such as hsTAF5 inhibits TFIID promoter-binding activity, thereby reducing sequence-specific DNA binding at RNA polymerase II regulatory regions.
What is the role of NELF in transcription?
NELF competes with elongation for paused polymerase, controlling promoter-proximal pausing and thus negatively regulating the binding of sequence-specific factors.
How is Ets1 involved in T-cell differentiation?
Ets1 is dynamically recruited to both nucleosome-occupied and nucleosome-depleted enhancers, mediating a transcriptional program switch during early T-cell differentiation.
What diseases are associated with dysregulation of this process?
Cancer, immune disorders, and developmental abnormalities have been linked to aberrant negative regulation of sequence-specific DNA binding.
What experimental methods study this process?
ChIP-seq, EMSA, reporter assays, proteomics, and CRISPR screens are commonly used to investigate negative regulation of DNA binding.
Can CRISPR be used to study this GO term?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models enable precise dissection of genes mediating this negative regulation.
What is the SV40 early promoter model?
The SV40 early promoter is a model regulatory region used to study sequence-specific single-strand-binding proteins that stimulate transcription in vitro.
Why is negative regulation of DNA binding important?
It provides a rapid and reversible mechanism to control transcription initiation and elongation, influencing development, differentiation, and disease.
Conclusion
GO:1903026, negative regulation of RNA polymerase II regulatory region sequence-specific DNA binding, represents a critical layer of transcriptional control that modulates the accessibility of promoters and enhancers to sequence-specific DNA-binding proteins. Through mechanisms such as SUMOylation of TFIID subunits, competitive inhibition by NELF, and dynamic transcription factor recruitment, cells can fine-tune gene expression programs in response to developmental and environmental cues. Dysregulation of this process contributes to cancer, immune disorders, and developmental defects, making it a compelling area for therapeutic intervention. Leveraging CRISPR-based models and advanced genomic methods, researchers can now dissect the precise roles of individual genes and pathways involved in this regulatory process, paving the way for novel discoveries and targeted therapies.
References
- 1. Gaillard C et al.. 1990. Sequence-specific single-strand-binding protein for the simian virus 40 early promoter stimulates transcription in vitro.. J Mol Biol 215(2):245-55 PMID: 2170663
- 2. Li J et al.. 2013. Kinetic competition between elongation rate and binding of NELF controls promoter-proximal pausing.. Mol Cell 50(5):711-22 PMID: 23746353
- 3. Boyer-Guittaut M et al.. 2005. SUMO-1 modification of human transcription factor (TF) IID complex subunits: inhibition of TFIID promoter-binding activity through SUMO-1 modification of hsTAF5.. J Biol Chem 280(11):9937-45 PMID: 15637059
- 4. Cauchy P et al.. 2016. Dynamic recruitment of Ets1 to both nucleosome-occupied and -depleted enhancer regions mediates a transcriptional program switch during early T-cell differentiation.. Nucleic Acids Res 44(8):3567-85 PMID: 26673693
